BROWSE 2024 PROGRAMS Now into our 8th year, CHI’sImmuno-Oncology Summit Europeis the premier event for immuno-oncology professionals who want to learn about the latest advancements and innovations in the field. The Summit will take place on23-25 April 2024 in London, one of the world’s le...
home / conference / esmo-immuno-oncology-congress Content TypeBMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy By Chris Ryan January 4th 2025 BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced ...
The Pharmacy Times® Immuno-oncology Resource Center is a comprehensive resource for clinical news and expert insights on treatments that harness the body's immune system to fight cancer.
conference program, we are struck by the fact that, despite these challenges, there remains a strong desire to continue to find effective therapeutics forsolid tumors. The 13th Annual 2025 Immuno-Oncology Summit showcases successes inpreclinicalandclinicalstudies grounded in a deep understanding of ...
Abstract Book of the ESMO Immuno-Oncology Congress 2024, 11-13 December 2024Publication of this Abstract book is supported by the European Society for Medical Oncology Volume 24, Supplement, December 2024 Previous vol/issue Next vol/issue
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The"2nd Annual ImmunoBio Series"conference has been added toResearchAndMarkets.com'soffering. Introducing the 2nd Annual ImmunoBio Series, a groundbreaking event uniting t...
Conference Registration: https://events.marketsandmarkets.com/immuno-oncology-conference-germany/register During the two-day conference, attendees will have the opportunity to gain insights from keynote presentations, panel discussions, and interactive sessions led by renowned experts in immuno-oncology....
Conference Registration: https://events.marketsandmarkets.com/6th-annual-immuno-oncology-conference-boston/register Several combination techniques, pre-clinical and translational immune-oncology advancements, updates in cellular and viral therapeutics, vaccine development, and personalized immunotherapy would also...
Immuno-Oncology Latest News Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC By Ashling Wahner December 24th 2024 Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer. Nivolumab/...
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, MD, November 21, 2024 – I-Mab (NASDAQ: IMAB, the “Company”), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatme...